Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

Logan, Michael; Mackinder, Mary; Clark, Caspar; Kountouri, Aikaterini; Jere, Mwansa; Ijaz, Umer Zeeshan; Hansen, Richard; McGrogan, Paraic; Russell, Richard K.; Gerasimidis, Konstantinos

doi:10.1186/s12876-022-02334-6

Cited by 11 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum biomarkers are particularly important where both skin and gut are affected in the disease pathogenesis or manifestation. For example, fatty acid binding proteins, which are serum biomarkers of inflammation and epithelial barrier dysfunction ( Baran et al., 2019 ; Lee et al., 2021 ), are important factors in both skin and gut involvement ( Logan et al., 2022 ; Yin et al., 2022 ), and they may serve as early predictors of SkAE following anti-TNF treatment.…”

Section: Introductionmentioning

confidence: 99%

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Reiss

Rob²,

Kolář³

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of patients suffer from unpredictable skin adverse events (SkAE). For this purpose, we analyzed temporal dynamics of skin microbiota and serum markers of inflammation and epithelial barrier integrity during anti-TNF therapy and SkAE manifestation in IBD patients. We observed that the skin microbiota signature of IBD patients differs markedly from healthy subjects. In particular, the skin microbiota of CD patients differs significantly from that of UC patients and healthy subjects, mainly in the retroauricular crease. In addition, we showed that anti-TNF-related SkAE are associated with specific shifts in skin microbiota profile and with a decrease in serum levels of L-FABP and I-FABP in IBD patients. For the first time, we showed that shifts in microbial composition in IBD patients are not limited to the gut and that skin microbiota and serum markers of the epithelium barrier may be suitable markers of SkAE during anti-TNF therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Reiss

Rob²,

Kolář³

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…After the intestinal mucosa is damaged, I-FABP quickly enters the blood circulation through the cell membrane, capillaries, lymphatic capillaries, and portal vein (7). Therefore, the levels of I-FABP in the blood reflect the degree of intestinal mucosal damage (8).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of short-chain polypeptide-based EEN formulas in alleviating intestinal injury in children with Crohn’s disease: a single-center study in China

Yang

Cao

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Short-chain polypeptides are composed of three to nine amino acids, which can be absorbed by the intestinal tract without digestive enzymes and ATP energy. Crohn’s disease (CD) is a chronic non-specific disease derived from inflammation and damage of the gastrointestinal tract. In this study, we aim to investigate the effect of short-chain polypeptide-based exclusive enteral nutrition (EEN) formulas on intestinal injury in Chinese children with active CD. From January 2013 to January 2019, a total of 84 consecutive children with a diagnosis of Crohn’s disease (CD) in the Department of Pediatric Gastroenterology, Children’s Hospital of Nanjing Medical University, were divided into mild and moderate-to-severe active CD groups. Each group was further divided into two subgroups: drug group and short-chain polypeptide plus drug group. Tests were carried out on the levels of intestinal fatty acid binding protein (I-FABP) in the blood, fecal calprotectin (FC), and occludin protein in the intestinal mucosa 1 day before treatment and 8 weeks after treatment. Endoscopic and histopathological observations were detected to compare the changes in intestinal injury in children with active CD. After 8 weeks of treatment, the SES-CD scores and Chiu scores of the ileocecal area and terminal ileum of children with mild active CD and the ileocecal area of children with moderate-to-severe active CD in short-chain polypeptide plus drug group were significantly lower than those in the drug group. The OD value of occludin in the terminal ileum and ileocecal area of children with mild active CD and the ileocecal area of children with moderate-to-severe active CD after short-chain polypeptide-based EEN formulas and drug treatment was significantly higher than those in the drug group (p < 0.05). Meanwhile, the levels of FC and I-FABP were significantly decreased (p < 0.05). The results showed that short-chain polypeptide-based EEN formulas effectively alleviate intestinal injury in children with active CD.

show abstract

“…5 In another study, urinary and plasma I-FABP were assessed among 138 children with IBD and CeD (47 with CD, 11 with UC, 12 with newly diagnosed CeD, 40 with established CeD and 28 without IBD or CeD), plasma I-FABP levels were significantly higher in the children with newly diagnosed CeD and those with CD only when compared to those without IBD or CeD. 10 Otherwise, urinary and plasma I-FABP levels did not differ between the rest of the groups, which is consistent with the results in the current study. The present study was limited by small sample size with predominately patients with CD of mild disease severity and other available biomarkers, such as fecal calprotectin, were not available for comparison.…”

mentioning

confidence: 99%

“…A recent study found that urinary I-FABP levels fall in young adults with active CD following 8 weeks of exclusive enteral nutrition, suggesting that it may be a sensitive indicator of disease activity [ 5 ]. In another study, urinary and plasma I-FABP were assessed among 138 children with IBD and CeD (47 with CD, 11 with UC, 12 with newly diagnosed CeD, 40 with established CeD and 28 without IBD or CeD), plasma I-FABP levels were significantly higher in the children with newly diagnosed CeD and those with CD only when compared to those without IBD or CeD [ 10 ]. Otherwise, urinary and plasma I-FABP levels did not differ between the rest of the groups, which is consistent with the results in the current study.…”

mentioning

confidence: 99%

Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease

Keenan

Day

2022

Intest Res

View full text Add to dashboard Cite

consent and assent were obtained from parents and children, respectively. Participants were categorized into 5 groups: active IBD, inactive IBD, non-IBD, healthy sibling (HS), and celiac disease (CeD). Patients with IBD were diagnosed based on the revised Porto criteria. 1 The active IBD group included those with newly diagnosed untreated IBD or those with relapsed disease requiring treatment to reinduce remission. The inactive IBD group included participants with known IBD who were in clinical remission based on clinical indexes (Pediatric Crohn' s Disease Activity Index [PCDAI] < 10 for CD or Pediatric Ulcerative Colitis Activity Index [PUCAI] < 10 for UC) and had no alteration to their IBD medications 3 months prior to enrolment. Children who underwent investigations for gastrointestinal symptoms and in whom IBD was excluded were categorized as the non-IBD group. Siblings of children with known IBD who were reported to be healthy were enrolled into the HS group. Children with newly diagnosed untreated CeD (based on any positive celiac serologies and histological modified Marsh-Oberhuber classification ≥ 2) were included as a disease control group.Baseline demographics including clinical (PCDAI and PU-CAI) and endoscopic disease activity (Simple Endoscopic Score for CD [SES-CD] and Mayo endoscopic score) were recorded. All disease groups provided baseline blood and urine samples, whilst HS group provided a urine sample only. Urine samples were collected and stored at 4°C within 24 hours of participant' s clinic appointment. Received samples were immediately aliquoted and stored at -80°C. Samples for analysis were

show abstract

Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

Cited by 11 publications

References 39 publications

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Efficacy of short-chain polypeptide-based EEN formulas in alleviating intestinal injury in children with Crohn’s disease: a single-center study in China

Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease

Contact Info

Product

Resources

About